NCT01344876View on ClinicalTrials.gov

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Multiple MyelomaNon-Hodgkin LymphomaAcute Myeloid LeukemiaAcute Lymphoid LeukemiaChronic Myeloid Leukemia
Interventions
DRUG

OPB-51602

once daily during the treatment period

Trial Locations (2)

Unknown

Nagoya

Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY